GlaxoSmithKline Plc said on Wednesday the U.S health regulator approved its lung disease drug Trelegy Ellipta for expanded use, making it the first inhaler delivering three drugs at once to be ...
AstraZeneca Plc said on Thursday its asthma treatment for a chronic inflammatory disease of the nasal passage linings, or sinuses, met main goals in a late-stage study.
A lip flip is more affordable and less painful than lip fillers — also, the end result tends to have a more natural look.
Telemedicine significantly improved quality of life and inhaler technique in advanced COPD patients compared to traditional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback